Xenotransplantation

Xenotransplantation transplants living organs, tissue or cells from one species into another — specifically, from multiplex gene-edited pigs into humans — to address a chronic shortage of human donor organs that leaves dozens of patients dying on transplant waitlists every day. CRISPR-Cas9 multiplex genome editing has moved the field from research concept to clinical reality: eGenesis received FDA IND clearance for its lead candidate EGEN-2784, a genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program. United Therapeutics’ 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, a Phase 1/2/3 adaptive (“phaseless”) design for pig-heart xenotransplantation. In China, Chengdu-based Zhongke Aoge Biotech has kept a gene-edited pig kidney functioning in a non-human primate recipient for more than 600 days in collaboration with Huazhong University of Science and Technology’s Tongji Hospital, with all kidney-function indicators reported normal throughout. The engineering challenge these programs share is defeating several distinct rejection mechanisms at once: hyperacute rejection driven by human antibodies against pig cell-surface sugars (targeted by knocking out the GGTA1, CMAH and B4GALNT2 glycan-synthesis genes), acute vascular rejection and clotting incompatibility (addressed by adding human coagulation-regulator genes THBD and PROCR), cellular immune attack (blocked by human complement regulators CD46/CD55/CD59 and tolerance molecules HLA-E/CD47), and the biosafety risk of porcine endogenous retroviruses (PERVs), which CRISPR-Cas9 can now inactivate across all copies in the donor genome.

The key directions of xenotransplantation are:

1. Multiplex glycan knockout: eliminating the pig-specific sugar antigens (alpha-Gal and related glycans) that trigger immediate hyperacute rejection by human antibodies.
2. Human transgene integration: adding human complement-regulator, coagulation-regulator and immune-tolerance genes to the pig genome so the organ is recognized as “self” by the human immune and clotting systems.
3. PERV inactivation: using CRISPR-Cas9 to disable every copy of the porcine endogenous retrovirus in the donor cell genome, eliminating the risk of cross-species viral transmission.
4. Designated pathogen-free (DPF) breeding: raising donor pigs in sealed, monitored barrier facilities to guarantee the organ is free of zoonotic pathogens at the time of transplant.

Sectoral value chain#

[CRISPR Design & Genome Engineering] ──> [Nuclear Transfer (SCNT)] ──> [Raising Gene-Edited Pigs]
                │                                     │                              │
       (Vectors, cell lines)                (Embryos, surrogates)          (Sterile DPF conditions)
                                                                                      │
[Human Transplantation] <──── [Organ Procurement & Perfusion] <─────────────────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Multiplex genome editing: introducing dozens of genetic changes into a single cell line simultaneously, requiring high-fidelity Cas nucleases and base editors to avoid chromosomal translocations and off-target mutations.
• Designated pathogen-free (DPF) barrier technology: closed-system pig facilities with positive air pressure, HEPA H14 filtration, effluent decontamination and autoclaved feed, with animals tested monthly against a panel of 30+ swine pathogens.
• Co-stimulation blockade immunosuppression: next-generation monoclonal antibodies (e.g., anti-CD40/anti-CD40L agents such as tegoprubart) that selectively block T- and B-cell co-stimulatory activation pathways, preventing xenograft rejection without fully suppressing the human immune system.

The xenotransplantation industry relies on the following technology stack:

1. Somatic cell nuclear transfer (SCNT):
   • The only method for producing viable cloned pig offspring from deeply edited cell lines: a fibroblast nucleus carrying the edits is microinjected into an enucleated oocyte, electrofused, chemically activated, cultured to blastocyst stage, and implanted in a surrogate sow.
2. Porcine endogenous retrovirus (PERV) inactivation:
   • CRISPR-Cas9 is used to simultaneously cut and disrupt every copy of the PERV pol gene integrated in the donor pig genome, eliminating replication risk and making organs safe for an immunosuppressed human recipient.
3. Normothermic ex vivo organ perfusion:
   • Instead of classic ice storage (which causes ischemic tissue damage), xenografts are connected to a mobile Organ Care System that continuously circulates warm, oxygenated donor blood enriched with nutrients and anti-inflammatory hormones, minimizing vascular injury during transport.